The pitch session will offer a showcase of 10 - 15 promising startups from Central Europe, focusing on the development of new drugs, diagnostics, and other medical technologies. The pitch session will be closely monitored by a jury composed of experienced investors, who will announce the three best presentations.
You can register your projects here.
Prague.bio Conference 2024 will offer two keynote speakers: Christian A. Stein, CEO of Ascenion, GmbH and Petr Jansa, the co-founder of Pallando Therapeutics, Head of Chemistry at BridGene Biosciences or Advisor for the California Life Sciences FAST program.
More information can be found here.
This year will also feature a panel discussion with representatives of investment funds who are involved in investing in Life Sciences.
We are excited to have Sebastian Kreuz from Boehringer Ingelheim Venture Fund, Agnes Oertli from LSA Ventures, Roman Smola from Tensor Ventures and Nicolas Beuzen from i&i Biotech Fund to share their wealth of experience with us.
The second edition of the Prague.bio Conference will once again feature a panel discussion with representatives of law firms who specialize in intellectual property. Last year, the IP discussion was among the most acclaimed parts of the program, and we believe it will be the same this time.
We will provide more detailed information soon.
Participants of the Prague.bio Conference can look forward to a poster session, which will feature a showcase of approximately twenty Czech and international scientific projects and startups that are trying to translate innovative ideas from laboratories into practice.
We will provide more detailed information soon.
Each participating investor will have 6 time slots during a one-hour session to connect with start-ups and teams of their choice. Various spectrum of investors (VC, Family offices, Angel) will participate.
The event is about networking. Experienced investors and people from leading pharmaceutical and diagnostic companies will assist scientists in commercializing their ideas. For business representatives, the event provides a platform for exchanging views and the opportunity to establish further collaborations.
We will provide more detailed information soon.
CONFERENCE AGENDA
After registration, please accept our invitation for morning coffee.
The official opening of the event will follow the registration of participants and morning coffee.
The first keynote speaker will be Christian A. Stein, the CEO of Ascenion GmbH, one of the largest technology transfer institutions in Germany. Christian was the head of the patent and licensing office in the German Human Genome Project and president of ASTP. He has founded various successful biotechnology and other companies and now also serves as a board member of the Alliance for Transfer in Germany. At the conference, he will acquaint participants with the differences in conditions and needs when founding spin-offs from the perspective of founders, investors, and scientists.
See below for more information.
The second year of Prague.bio Conference will also feature a panel discussion with representatives of investment funds from Central Europe who are involved in investing in Life Sciences.We are excited to have Sebastian Kreuz from Boehringer Ingelheim Venture Fund, Agnes Oertli from LSA Ventures, Roman Smola from Tensor Ventures and Nicolas Beuzen from i&i Biotech Fund to share their wealth of experience with us.
See below for more information.
Enjoy a coffee and chat with other participants of our conference.
A short break filled with delicious coffee is followed by a talk of Alexander Fetkovsky, CEO of SanaClis, one of our esteemed sponsor. SanaClis is a global CRO with an integrated clinical supply chain, headquartered in Bratislava, Slovakia. The company is a key player in the R&D space, providing a comprehensive range of end-to-end solutions for clinical trials throughout the entire life cycle of the study.
See below for more information.
This year, we feature twelve promising technologies spanning the development of new drugs, diagnostics and materials from innovators in the Czech Republic, Germany, Austria, Slovakia and Poland. Our presenters will showcase cutting-edge solutions for oncology, infectious diseases, and other critical health issues. Join us to discover the future of healthcare innovation from CARTemis Therapeutics, Elyte diagnostics, IOCB Prague, MIM Neurosciences /UCT Prague, nCage Therapeutics, and Sophomer.
After half of the program, it is time to take a break and recharge your batteries. We wish you a bon appetit.
A short break filled with the lunch is followed by a talk of Bartek Madej, Senior Director,
Digital Health Lead International Markets at Bristol Myers Squibb, our distinguished general partner. Bristol Myers Squibb is a global biopharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.See below for more information.
The second keynote speaker of Prague.bio Conference 2024 will be Petr Jansa. His expertise builds on collaboration with Prof. Antonín Holý and the development of new drugs at Gilead Sciences. Currently, he is intensely involved in the start-up scene, whether as Head of Development at Bridgene Biosciences, as an advisor to the California Life Science FAST program (a program for early-stage start-ups), and currently serving as Executive Director of Medicinal Chemistry at Biomea Fusion (publicly traded Biotech company).
See below for more information.
This year, we feature twelve promising technologies spanning the development of new drugs, diagnostics and materials from innovators in the Czech Republic, Germany, Austria, Slovakia and Poland. Our presenters will showcase cutting-edge solutions for oncology, infectious diseases, and other critical health issues. Join us to discover the future of healthcare innovation from Acellmed, Deep MedChem, LAM-X, Masaryk University Brno, Shealed and Smartbax.
Participants of the Prague.bio Conference 2024 can look forward to a Poster session, which will feature a showcase of approximately twenty Czech and international scientific projects and startups that are trying to translate innovative ideas from laboratories into practice.
A new feature this year is Speed dating. Each participating investor will have 6 time slots during a one-hour session to connect with start-ups and teams of their choice. Various spectrum of investors (VC, Family offices, Angel) will participate.The second edition of the Prague.bio Conference will once again feature law and IP panel discussion. Law and IP experts with various background will cover the topic of "Legal Specifics of Biotech Startup Financing Rounds“. The speakers will include Katarzyna Wójcik-Bąkowska (Wolf Theiss), Richard Fagerer (Dentons), Adrian Bradley (Cleveland Scott York), Joy Sharp (Faegre Drinker) and Mikuláš Vargic (Kristýna & Mikuláš advokáti).
See below for more information.
Special guest of Prague.bio Conference 2024 is Deborah Spencer, MBA, innovation expert and industrial partnership manager from the UK, who will share her experiences from the University of Oxford and other prestigious institutions. Deborah has over 20 years of experience in the life sciences, healthcare and medicine. More recently she has been focused on interdisciplinary working across the physical and life sciences. Working at the interface between industry and academia building extensive networks with a multitude of stakeholders.
See below for more information.
After the presentation of Deborah Spencer, it will be time for the official farewell to the second edition of the Prague.bio Conference 2024.
The event is about networking. The evening reception will be a great opportunity to make new contacts.
NEWS
AUDIENCE
Prague.bio Conference 2024 offers a unique opportunity for the exchange of experiences and information among all professionals involved in the development of new drugs, diagnostics, medical technologies, and other areas of biotechnology.
Startups
and
spinoffs
Biotech SMEs
and
large corporates
Investors
focusing
on biotech
IP and law
professionals
Technology
transfer
offices
Scientists
and
students
Policy
makers
Media